Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation - Takeaways - MDSpire

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation

  • By

  • Yi-Lun Chiang

  • Tzu-Hao Li

  • Yu-Wei Fang

  • Ya-Fang Liu

  • Jennifer Wu

  • Ming-Hsien Tsai

  • April 13, 2026

  • 0 min

Share

  • 1

    GLP-1 receptor agonists (GLP-1 RAs) are linked to a higher risk of psoriasis compared to dipeptidyl peptidase-4 inhibitors (DPP-4is).

  • 2

    Initiation of GLP-1 RAs is associated with a lower risk of pemphigus and bullous pemphigoid compared to DPP-4is.

  • 3

    The study utilized a large, real-world dataset to emulate a randomized trial comparing GLP-1 RAs and DPP-4is.

  • 4

    No significant differences were found for other inflammatory or autoimmune skin outcomes after multiple-testing correction.

  • 5

    The findings emphasize the need for ongoing skin monitoring in patients using incretin therapies for type 2 diabetes.

Original Source(s)

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation

  • by Yi-Lun Chiang, Tzu-Hao Li, Yu-Wei Fang, Ya-Fang Liu, Jennifer Wu, Ming-Hsien Tsai

  • April 13, 2026

Related Content

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

Survey on the current status of photoaging in young Asian women and intervention effects of non-ablative bipolar radiofrequency combined with ablative fractional CO₂ laser: a retrospective study

Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study